Symlin

Space breeding concept Space conditions can induce mutations of plant seeds, and can be helpful to accelerate the crop breeding. It may be possible to obtain rare mutants that may make a great breakthrough in important economic characters of the crop, such as yield and quality, which are difficult to get using the other breeding methods on ground. The plant seeds are sent in the space on a space rocket, and when the rocket is back on earth, plant seeds or in vitro shoot cultures or microspores are assessed to determine the influence of cosmic rays in generating new mutants. There are only few countries involved in this type of work, e.g. China. Since 1987, 13 recoverable satellites have been used by Chinese scientists and researchers to carry more than 80 kg of plant seeds belonging to over 70 species, involving main cereal, fiber, oil, vegetable, and fruit crops. Through ground planting and selecting experiments by breeders in more than 50 research units covering more than 20 provinces, cities and regions in China, good achievements have been made. More than 20 mutant cultivars were developed and officially released. In rice, a new cultivar EYH No.1, has been released due to its grain yield 14.5 t ha-1 ; . Space breeding involves big investment and good technological support. The chances of conducting the space experiment are very limited. It is important to make ground simulation on space factors to conduct research work for revealing the mechanism of space-induced mutation and applying it for plant breeding. In cassava, somatic embryogenic cultures could be used for cosmic radiation treatment at the ground simulation facilities. In these four studies, approximately one-half of all participants who received symlin evidenced an early reduction in hba1c. Different kinds of medication can be used to achieve this. Papaverin was the first to be used; nowadays it is used in a combination with phentolamine Androskat ; , leading to a more stable erection. Prostaglandin Caverject ; is also used in this regard. In all cases, the injection therapy works by narrowing the bloodvessels that drain the blood from the cavernous bodies, in much the same way Viagra, mentioned above, does. TV Total Number of half hours viewed per week for all time periods, developed from a weighted average of the number of half hours viewed on an average day. Men Range 86 + 57-85 39-56 20-38 0-19 48 + 0-47 Share of Volume 46.0% 24.5% 16.6% Average Penetration 131.5 69.9 47.3 Range 94 + 60-93 39-59 20-38 0-19 49 + 0-48 Women Share of Volume 47.1% 24.6% 16.0% Average Penetration 142.2 74.2 48.2.

References. 1. Yarotsky, D.A., "Perturbations of ground states in weakly interacting quantum spin systems", J. Math. Phys. 45, 2134-2152 2004 ; 2. Yarotsky, D.A., "Uniqueness of the ground state in weak perturbations of non-interacting gapped quantum lattice systems'', to appear in J. Stat. Phys. 1. Kolb BA. 2003. Preservation of Reproductive Options in Oncology Patients. Reproductive Medicine Reviews. 11: 43-56. 2. Kolb BA. 1997. Prevention of Pelvic Adhesions. The Resident Reporter; 2: 2228. 3. Kolb BA and Paulson RJ. 1996. Unstimulated In Vitro Fertilization Revisited. Reproductive Medicine Reviews. 5: 129-138. 4. Kolb BA. 1994. Implantation: The Next Frontier. Resident & Staff Physician; January Supplement, 7-12 and symmetrel. Cheap symlin online But when Tryphon knew that Simon stood up instead of his brother Jonathas, and that he would war against him: he sent messengers unto him, saying: Whereas we have kept Jonathas thy brother, it is for money that he is owing in the kings * accompte, concerning the business that he had in hand. Wherefore send now an hundred talents of silver, and his two sons for surety, that when he is let forth he shall not forsake us: and we shall send him again. Nevertheless Simon knew, that he disassembled in his words: yet commanded he the money and the children to be delivered unto him: least he should be the greater enemy against the people of Israel, and said: because he sent him not the money and the children, therefore is Jonathas dead. So Simon sent him the children and an hundred talents, but he dissembled and would not let Jonathas go. Afterward came Tryphon into the land, to destroy it, and went round about by the way, that leadeth unto Adora: But wheresoever they went, thither went Simon and his host also. Now they that were in the castle, sent messengers unto Tryphon, that he should make haste to come by the wilderness, and to send them victuals: And Tryphon made ready all his horsemen to come that same night. Nevertheless it was a very great snow, so that he came not in Galaadithim. And when he drew nye Baschama, he slew Jonathas and his sons there, and then turned for to go into his own land. Then sent Simon for to set his brothers dead corpse, and buried it in Modin his fathers city. So all Israel bewailed him with great lamentation, and mourned for him very long. And Simon made upon the sepulchre of his father and his brethren a building high to look unto of free stone behind and before: and set up * seven pillars, one against another, for his father.

Utilization of the preferred agent increased from 0% to 59%, annual drug costs decreased by 5, 000 16% ; , and lifeyears saved increased by 154 7.4% ; . The discounted cost per life-year saved decreased by , 100 and synagis. In january 2004, amylin withdrew its application to sell symlin in switzerland when questions arose about side effects including nausea and hypoglycemia low blood sugar. I. M. has recently consulted, or been involved in quinolone research programmes, for Aventis, Bayer, BMS, Daiichi Pharmaceutical Co. Ltd., GeneSoft and GlaxoSmithKline in addition to work with other companies on non-quinolone antibacterials. G. S. T. consults for Bayer, BMS, Chiron, GeneSoft, Replidyne and Roche and synvisc.

Symlin is used in conjunction with insulin to control glucose in patients with type 2 diabetes who use insulin, and in patients with type 1 diabetes. Symlin therapy should only be considered in patients with insulin-using type  2 or type  1 diabetes who fulfill the following criteria: have failed to achieve adequate glycemic control despite individualized insulin management; are receiving ongoing care under the guidance of a health care professional skilled in the use of insulin and supported by the services of diabetes educator s and tace.

Cavallaro, R; Aschauer, HN; McCreadie, RG; Ohlraun, S; Ferrier, N; Masellis, M; Verga, M; Scharfetter, J; Rietschel, M; Lovlie, R; Levy, UH; Meltzer, HY; Kennedy, JL; Steen, VM; Macciardi, F. Pharmacogenetics of tardive dyskinesia: Combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology; 2002; 27 1 ; : 105-119 N.72. Losa, M; Mortini, P; Barzaghi, R; Gioia, L; Giovanelli, M. Surgical treatment of prolactin-secreting pituitary adenomas: Early results and long-term outcome. J.Clin.Endocrinol.Metab.; 2002; 87 7 ; : 3180-3186 N.73. Magnani, G; Cursi, M; Leocani, L; Volonte, MA; Comi, G. Acute effects of L-dopa on event-related desynchronization in Parkinson's disease. Neurol i.; 2002; 23 3 ; : 91-97 N.74. Martino, G; Adorini, L; Rieckmann, P; Hillert, J; Kallmann, B; Comi, G; Filippi, M. Inflammation in multiple sclerosis: the good, the bad, and the complex. Lancet Neurol.; 2002; 1 8 ; : 499-509 N.75. Mascalchi, M; Moretti, M; Della, Nave, R; Lolli, F; Tessa, C; Carlucci, G; Bartolini, L; Pracucci, G; Pantoni, L; Filippi, M; Inzitari, D. Longitudinal evaluation of leukoaraiosis with whole brain ADC histograms. Neurology; 2002; 59 6 ; : 938-940 N.76. Massat, I; Souery, D; Del-Favero, J; Oruc, L; Noethen, MM; Blackwood, D; Thomson, M; Muir, W; Papadimitriou, GN; Dikeos, DG; Kaneva, R; Serretti, A; Lilli, R; Smeraldi, E; Jakovljevic, M; Folnegovic, V; Rietschel, M; Milanov, V; Valente, F; Van Broeckhoven, C; Mendlewicz, J. Excess of allele1 for alpha 3 subunit GABA receptor gene GABRA3 ; in bipolar patients: a multicentric association study. Mol.Psychiatry; 2002; 7 2 ; : 201-207 N.77. Massat, I; Souery, D; Del-Favero, J; Van Gestel, S; Serretti, A; Macciardi, F; Smeraldi, E; Kaneva, R; Adolfsson, R; Nylander, PO; Blackwood, D; Muir, W; Papadimitriou, GN; Dikeos, D; Oruc, L; Segman, RH; Ivezic, S; Aschauer, H; Ackenheil, M; Fuchshuber, S; Dam, H; Jakovljevic, M; Peltonen, L; Hilger, C; Hentges, F; Staner, L; Milanova, V; Jazin, E; Lerer, B; Van Broeckhoven, C; Mendlewicz, J. Positive association of dopamine D2 receptor polymorphism with bipolar affective disorder in a European multicenter association study of affective disorders. Am.J.Med.Genet.; 2002; 114 2 ; : 177-185 N.78. Mattioli, F; Capra, R; Rovaris, M; Chiari, S; Codella, M; Miozzo, A; Gregorini, G; Filippi, M. Frequency and patterns of subclinical cognitive impairment in patients with ANCA-associated small vessel vasculitides. J.Neurol i.; 2002; 195 2 ; : 161166 N.79. Mazzucchelli, C; Vantaggiato, C; Ciamei, A; Fasano, S; Pakhotin, P; Krezel, W; Welzl, H; Wolfer, DP; Pages, G; Valverde, O; Marowsky, A; Porrazzo, A; Orban, PC; Maldonado, R; Ehrengruber, MU; Cestari, V; Lipp, HP; Chapman, PF; Pouyssegur, J; Brambilla, R. Knockout of ERK1 MAP kinase enhances synaptic plasticity in the striatum and facilitates striatal-mediated learning and memory. Neuron; 2002; 34 5 ; : 807820 N.80. Meldolesi, J. Rapidly exchanging Ca2 + stores: Ubiquitous partners of surface channels in neurons. News Physiol i.; 2002; 17 ; : 144-149 N.81. Menegon, A; Verderio, C; Leoni, C; Benfenati, F; Czernik, AJ; Greengard, P; Matteoli, M; Valtorta, F. Spatial and temporal regulation of Ca2 + calmodulin-dependent protein kinase II activity in developing neurons. J.Neurosci.; 2002; 22 16 ; : 70167026 N.82. Meraviglia, MV; Maggi, E; Bellomo, G; Cursi, M; Fanelli, G; Minicucci, F. Autoantibodies against oxidatively modified lipoproteins and progression of carotid restenosis after carotid endarterectomy. Stroke; 2002; 33 4 ; : 1139-1141 N.83. Moro, F; Carrozzo, R; Veggiotti, P; Tortorella, G; Toniolo, D; Volzone, A; Guerrini, R. Familial periventricular hetero and targretin and symlin.
And requirement on account of condemnation. Within the ambit of these parameters, orders are placed on the production units every year. 1.8 In the subsequent chapters the Committee will deal with the current and perspective problems relating to productions, maintenance, quality assurance etc. in these Production Units and workshops.
Virologic success may be higher with Lpv r than ATV r. On the other hand, while the 48-week data from the CONTEXT trial24, 25 failed to show non-inferiority of either once or twice daily FPV r to Lpv r using the primary endpoint average area under the curve minus baseline ; , despite higher rates of baseline PI resistance and ARV experience in the FPV r twice daily arm, it achieved rates of HIV-RNA suppression to less than 50 copies ml similar to those achieved with Lpv r 46 and 50%, respectively ; . An analysis of the baseline resistance data failed to show that particular mutations were predictive of success with one arm more than the other; however, the presence of M46I L or L90M reduced the chance of virologic success with either FPV r or Lpv r. Taken together, these two studies indicate that three boosted PIs Lpv r, ATV r and twice daily FPV r ; appear to be relatively similar in achieving an HIV-RNA below 50 copies ml, and that use of once daily FPV r should be avoided in PI-experienced patients. Further, the particular resistance profile of the patient should be considered when selecting the boosted PI to use, and and tarka. From the internal medicine, university of insubria, varese, italy.

Those alterations which are produced by the simple fact o operative lesion. With regard to this I can confirm the observation of Delanoe for trypanosomes. When the puncture of the peritoneum is repeated several times, alteration and death of the Leishmanias take place by the probable extrusion of trypanolytic substances from the leucocytes into the plasma, while if the peritoneum be not punctured the flagellates that have remained free are preserved living and with normal structure, and in this condition are engulfed by the leucocytes. Of the liquid extracted from the peritoneal cavity I have made preparations in the fresh condition and smears on slides which I have fixed while still wet in vapour of osrnic acid for five seconds, and afterwards, when dry, in absolute alcohol for a quarter of an hour--a method of technique which also gives very good results for staining- the flagellates in the cultures. The smears should be very thin, and it is often useful to follow the staining by very short differentiation in the solution of tannin according to Unna. I have made examinations of the peritoneal liquid every five minutes after the injection up to two hours aud then every half hour up to four hours, repeating the experiment in a fairly numerous series of animals. In the fresh state it is seen in the first few minutes after the injection of the culture that the number of the Leishmanias, truly enormous in 2-4 c.c. of a rich culture, is already to some extent diminished, and not by the fact of the greater dilution alone; very many flagellates are still free and very many are mobile, perhaps even more than in the cultural liquid, but it is not difficult to come upon others adhering or united to leucocytes, either by the posterior end or by the flagellum, preserving, however, in all cases a certain mobility. When they are completely engulfed in the leucocytes they are seen in its protoplasm as rounded bodies, but at this point it is easier to recognise them and to follow their modifications in the stained preparations. In the fresh state I have found in the guinea-pig some Leishmanias free and mobile up to an hour.

Amylinomimetics SYMLIN Biguanides metformin hcl tab 1000 mg metformin hcl tab 500 mg metformin hcl tab 850 mg metformin hcl tab sr 24hr 500 mg metformin hcl tab sr 24hr 750 mg RIOMET SOL Metformin HCl ; Incretin Mimetics BYETTA BYETTA Insulins HUMALOG INJ 100 ML Insulin Lispro Human HUMALOG MIX SUS 75 25 Insulin Lispro Protamine & Lispro Human HUMALOG PEN INJ 100 ML Insulin Lispro Human 02 INJ 10MCG Exenatide ; INJ 5MCG Exenatide ; 03 PA ; INJ 0.6MG ML Pramlintide Acetate ; 03 PA. 4. Hypoglycemics, Insulin Chris Andrews, from Provider Synergies, presented the evaluation and recommendation for this class. Chris Andrews stated that Byetta and Symlin have been reclassified, for review purposes, to another class. They will therefore be reviewed at a later date. Chris also stated that there have been three new insulins since the last class review; Apidra, Exubera and Levemir. He reviewed their respective clinical profiles. L. Sobel asked about pricing for Lilly's insulins, thinking they had recently lowered their price. Chris Andrews pointed out the savings for this class when Novo Nordisk's insulins were preferred. Chris was also able to present current data on market share for Novo Nordisk products vs. Lilly. The PDL was able to move significant market share to Novo Nordisk, even with the "grandfathering" that the P&T Committee had previously approved for Lilly's products. C. Sherter stated that this is a clear case where the PDL process has worked. L. Sobel had another question about Pregnancy Class for the different insulins, mentioning that Lilly's brand had a safer class B ; than Novo Nordisk's C ; . C Sherter stated that would be a specific situation where a prior authorization for a non-preferred product could be acquired, if desired. The committee motioned to approve and accepted Provider Synergies' recommendations as presented. The motion was passed with Peggy Memoli and Larry Sobel abstaining. No changes were made to this class. ON PDL: OFF PDL: Lantus, Novolin, Novolog, Novolog Mix Apidra, Exubera, Humalog, Humalog Mix, Humulin, Levemir and symmetrel. Included under "interest-bearing financial liabilities" in the consolidated balance sheets.

Oral Anti-Hyperglycemic Drugs. Many oral anti-hyperglycemic drugs are available to help patients with type 2 diabetes control their blood sugar levels. Most of these drugs are aimed at using or increasing sensitivity to the patient's own natural stores of insulin. Metformin is the only drug to date that achieves lower mortality rates. Oral type 2 diabetes drugs include: Biguanides metformin ; . Metformin increases tissue sensitivity to available insulin. Metformin also has beneficial effects on cholesterol, blood pressure, and clotting factors. It does not cause weight gain or hypoglycemia. Diarrhea and digestive problems are the most common side effects. Metformin produces lower mortality rates than other drugs, including insulin, and should be considered as first-line therapy for most patients with type 2 diabetes. Sulfonylureas glyburide, glipizide, glimepiride, repaglinide ; . Stimulate insulin secretion but can cause hypoglycemia more than other drugs. DPP-4 inhibitors sitagliptin ; . Also called gliptins, DPP4 inhibitors were first approved in 2006 and are the newest class of oral diabetes drugs. Like metformin, they do not cause weight gain and have low risks for hypoglycemia. Meglitinides repaglinide, nateglinide ; . Stimulate insulin secretion. These newer drugs are better than sulfonylureas in controlling glucose spikes after meals. Thiazolidinediones pioglitazone and rosiglitazone ; . Reduce insulin resistance. These drugs improve cholesterol levels and may reduce the risk for blood clots. However, they can cause swelling from fluid build-up, which can worsen heart failure or even precipitate it. They may also injure the liver. Alpha-glucosidase inhibitors acarbose and miglitol ; . Slow intestinal absorption of carbohydrates. Have only modest effects on diabetes and have gastrointestinal side effects. Can slightly raise HDL "good" ; cholesterol levels. Combinations of these drugs, particularly with metformin, are often used to increase effectiveness. A 2007 review in the Annals of Internal Medicine compared these various classes of medications. The review found that older drugs -- such as metformin and sulfonylureas -- are less expensive than and work as well as newer diabetes drugs. In particular, the review cited metformin as a safe and effective drug because it does not cause weight gain or too-low blood sugar. Metformin can also help lower LDL "bad" ; cholesterol. Injectable Anti-Hyperglycemic Drugs. In 2005, the FDA approved two new injectable drugs to help patients improve blood sugar control: Exenatide Byetta ; . Exenatide is the first drug in a new class of drugs called incretin mimetics. It lowers blood glucose levels by increasing insulin secretion. Exenatide is used in combination with oral antihyperglycemics, such as metformin or a sulfonylurea drug. Pramlintide Symlin ; . Pramlintide is a first-in-class drug that is a synthetic form of the hormone amylin. The drug is meant for patients who take insulin but still have difficulty controlling their glucose levels. Insulin Replacement. Insulin replacement may be required when natural insulin reserves are depleted. It is typically started in combination with an oral drug. Eventually, some patients may need to go on full insulin replacement. In addition to injectable forms of insulin, an inhaled insulin product Exubera ; is now available. Biguanides Metformin ; Metformin Glucophage ; is a biguanide, which works by reducing glucose production in the liver and by making tissues more sensitive to insulin. Many experts recommend it as a first choice for most patients with type 2 diabetes who are insulin resistant, particularly if they are overweight. Metformin achieves lower mortality rates from diabetes and all causes than other drugs. In one comparison study, it achieved the lowest mortality rates 8% ; compared to insulin 28% ; , a sulfonylurea 16% ; , and a thiazolidinedione 14% ; . Combinations with insulin-secreting drugs, other insulin-sensitizing drugs, or insulin itself are particularly effective. Metformin does not cause hypoglycemia or add weight, so it is particularly well-suited for obese patients with type 2 diabetes. In some studies, in fact, patients lost weight. ; Metformin also appears to have beneficial effects on cholesterol and lipid levels and may help protect the heart. Some research has suggested that it significantly reduces the risk for heart attack. It is also the first choice for children who need oral drugs and is proving to be very effective for women with polycystic ovary syndrome and insulin resistance. Side Effects. Side effects include: A metallic taste Gastrointestinal problems, including nausea, and diarrhea Interference with absorption of vitamin B12 and folic acid, which are important for protection against heart disease ; Rare reports of lactic acidosis, a potentially life-threatening condition, particularly in people with risk factors for it. Major studies, however, found no greater risk with metformin than with any of the other drugs used for type 2 diabetes. Certain people should not use this drug, including anyone with heart failure or kidney or liver disease. It is rarely suitable for adults over age 80. Sulfonylureas Sulfonylureas are oral drugs that stimulate the pancreas to release insulin. They are also first-line oral drugs. For adequate control of blood glucose levels, the drugs should be taken only 20 - 30 minutes before a meal. A number of brands are available, including chlorpropamide Diabinese ; , tolazamide Tolinase ; , acetohexamide Dymelor ; , glipizide Glucotrol ; , tolbutamide Orinase ; , glyburide Micronase ; , glimepiride Amaryl ; , and repaglinide Prandin ; . Most patients can take sulfonylureas for 7 - 10 years before they lose effectiveness. Combinations with small amounts of insulin or with other oral anti-hyperglycemic drugs such as metformin or a thiazolidinedione ; may extend their benefits. A combination of glyburide and metformin in one pill Glucovance ; is available. Glucovance may be particularly. The list of drugs below has been removed from the TLS after discussion by the committee. They were all previously classified as Red 7, not listed in the current BNF, and have never been published. Amlexanox Aphthasol ; - Aphthous ulcers, mucositis allergic rhinitis Cannabis extract Sativex ; Multiple sclerosis, neuropathic pain Cilomilast Asthma, COPD Colesevelam Cholestagel ; - Mildly elevated serum cholesterol Micafungin Funguard ; - Invasive fungal infections Morphine liposomal Depomorphine ; - Moderate to severe post op pain Nesiritide Natrecor ; - Acute treatment of congestive cardiac failure Pramlintide Symlin ; - Adjunct to insulin in type 1 & type 2 diabetes Prasterone Mylis, Anastar ; SLE Ranolazine Ranexa ; - First of a new class of drugs for treating stable angina Tegaserod Zelmac ; - Irritable bowel syndrome Zicotinide - Chronic pain. The results of this study indicate that tumor diameter 5 cm, tumor infiltration and differentiation are risk factors for lateral lymph node metastasis of advanced low rectal cancer. Lateral lymph node metastasis is significantly correlated with local recurrence and prognosis of advanced low rectal cancer. 15. Cheap symlin

3 Kupelian, Page, Araujo, et al. Low Sex Hormone-Binding Globulin, Total Testosterone, and Symptomatic Androgen Deficiency Are Associated with Development of the Metabolic Syndrome in Nonobese Men. J Clin Endocrinol Metab 2006 91: 843-850. 1. Anon JB, Jacobs MR, Poole MD, et al, for the Sinus and Allergy Health Partnership. Antimicrobial Treatment Guidelines for acute bacterial rhinosinusitis and AECB. Otolaryngol Head Neck Surg. 2004; 130 suppl ; : 1-45.
Site services a to z drug list drugs by condition drug side effects pill identifier interactions checker news & articles new drug approvals new drug applications fda drug alerts clinical trial results drug image search patient care notes medical encyclopedia medical dictionary medical videos - drug classification community forums for professionals drug imprint codes medical abbreviations veterinary drugs contact us news feeds advertise here recent searches malarone zosyn zyban drixoral symlin pepcid epogen ranexa temazepam nexavar viagra propecia lipitor xenical ephedrine toradol vistaril alcohol hyzaar avandamet rebetol zyprexa ziana rozerem seldane recently approved pristiq arcalyst xyntha simcor accretropin moxatag tekturna hct intelence recothrom flo-pred more.
C. Fiset thanks Chantale St. Michel for technical assistance with the manuscript. This work was supported by National Institutes of Health Grants HL-58224, HL-66035, and HL-67245 to M. A. Sussman ; , GM-54169 and HL-61476 to A. Yatani ; , HL-64140 to M. Periasamy ; , PO1 HL-47053 to H. H. Valdivia ; , and HL07752 to D. M. Plank ; and by American Heart Association Ohio Valley Affiliate Predoctoral Training Grant 0110127B to D. M. Plank ; National Grant 0040051N to M. A. Sussman ; . C. Fiset is a Research Scholar of the Heart and Stroke Foundation of Canada. M. A. Sussman is an Established Investigator of the American Heart Association REFERENCES 1. Antos CL, Frey N, Marx SO, Reiken S, Gaburjakova M, Richardson JA, Marks AR, and Olson EN. Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase A. Circ Res 89: 9971004, 2001. Aoyagi T, Yonekura K, Eto Y, Matsumoto A, Yokoyama I, Sugiura S, Momomura S, Hirata Y, Baker DL, and Periasamy M. The sarcoplasmic reticulum Ca2 -ATPase SERCA2 ; gene promoter is decreased in response to severe left ventricular pressure-overload hypertrophy in rat hearts. J Mol Cell Cardiol 31: 919926, 1999. Asai K, Yang G, Geng Y, Takagi G, Bishop S, Ishikawa Y, Shannon RP, Wagner TE, Vatner DE, Homcy CJ, and Vatner SF. -Adrenergic receptor blockade arrests myocyte damage and preserves cardiac function in the transgenic Gs mouse. J Clin Invest 104: 551558, 1999. Barrere-Lamaire S, Piot C, Leclercq F, Nargeot J, and Richard S. Facilitation of L-type calcium currents by diastolic depolarization in cardiac cells: impairment in heart failure. Cardiovasc Res 47: 336349, 2000. Bers DM. Excitation-Contraction Coupling and Cardiac Contractile Force. Dordrecht, The Netherlands: Kluwer, 1991. 6. Bers DM, Patton CW, and Nuccitelli R. A practical guide to the preparation of Ca2 buffers. In: Methods in Cell Biology, edited by Nuccitelli R. San Diego, CA: Academic, 1994, p. 428. 7. Bristow MA. -Adrenergic receptor blockade in chronic heart failure. Circulation 88: 895902, 2000. Bueckelmann DL, Nabauer M, and Erdmann E. Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation 85: 10461055, 1992. Dash R, Kadambi FJ, Schmidt AG, Tepe NM, Biniakiewicz D, Gerst MJ, Canning AM, Abraham WT, Hoit BD, Liggett SB, Lorenz JN, Dorn GW, and Kranias EG. Interactions between phospholamban and -adrenergic drive may lead to cardiomyopathy and early mortality. Circulation 103: 889896, 2001. Del Monte F, Harding SE, Schmidt U, Matsui T, Kang ZB, Dec GW, Gwathmey JK, Rosenzweig A, and Hajjar RJ. Restoration of contractile function in isolated cardiomyocytes from failing hearts by gene transfer of SERCA2a. Circulation 100: 23082311, 1999. Doi M, Yano M, Kobayashi S, Kohno M, Tokuhisa T, Okuda S, Suetsugu M, Hisamatsu Y, Ohkusa T, Kohno T, Michihiro M, and Matsuzaki M. Propranolol prevents the development of heart failure by restoring FKBP12.6-mediated stabilization of ryanodine receptor. Circulation 105: 13741379, 2002. Eichhorn EJ, Heesch CM, Barnett JH, Alvarez LG, Fass SM, Grayburn PA, Hatfield BA, Marcoux LG, and Malloy CR. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomAJP-Heart Circ Physiol VOL.
1. Symlin pramlintide acetate ; injection [Package insert]. San Diego, Calif.: Amylin, 2005. Accessed December 7, 2006, at: : symlin pdf SYMLIN-pi-combined . 2. Kruger DF, Gloster MA. Pramlintide for the treatment of insulin-requiring diabetes mellitus: rationale and review of clinical data. Drugs 2004; 64: 1419-32. Byetta exenatide injection ; [Package insert]. San Diego, Calif.: Amylin, 2006. Accessed December 7, 2006, at: : pi.lilly us byetta-pi . 4. Dungan K, Buse JB. Glucagon-like peptide 1-based therapies for type 2 diabetes: a focus on exenatide. Clin Diabetes 2005; 23: 56-62. American Diabetes Association. Standards of medical care in diabetes-- 2006 [Published correction appears in Diabetes Care 2006; 29: 1192]. Diabetes Care 2006; 29 supp 1 ; : S4-42. 6. White JR Jr, Davis SN, Cooppan R, Davidson MB, Mulcahy K, Manko GA, et al. Clarifying the role of insulin in type 2 diabetes management. Clin Diabetes 2003; 21: 14-21. LeRoith D, Levetan CS, Hirsch IB, Riddle MC. Type 2 diabetes: the role of basal insulin therapy. J Fam Pract 2004; 53: 215-22. Taking symlin at mealtimes replaces the absent or deficient amylin insulin is only part of the solution to treating diabetes.